A randomized, open-label, phase 2 study of emibetuzumab plus erlotinib (LY+E) and emibetuzumab monotherapy (LY) in patients with acquired resistance to erlotinib and MET diagnostic positive (MET Dx+) metastatic NSCLC.
暂无分享,去创建一个
G. Bepler | E. Smit | Keunchil Park | D. Camidge | J. Molina | V. Wacheck | J. Goldman | S. Wijayawardana | C. Lewanski | T. Morán | Xuejing Wang | J. Wallin | I. Demedts | K. Mileham | Ó. J. Vidal | H. Grosch | J. Mercurio